Currently, the IL-1 receptor antagonist anakinra, monoclonal antibodies against IFN-γ and IL-6 are all candidates for relieving excess inflammatory responses, and their curative effects in COVID-19 patients were highly anticipated (88, 89). Here, IFNG is linked to COVID-19.